CLL Monthly Minutes
A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Read More ›
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia. Read More ›
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia. Read More ›
Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end. Read More ›
Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia. Read More ›
Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact. Read More ›
Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features. Read More ›
By keeping themselves physically and emotionally healthy, caregivers can give their loved ones the best possible support when helping to care for them. Read More ›
The COVID-19 pandemic has resulted in several changes in how patients with chronic lymphocytic leukemia (CLL) are treated. Read More ›
Better identification of patients at high risk of disease progression and newer treatments may mean that fewer newly diagnosed patients must “watch and wait.” Read More ›